<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03190694</url>
  </required_header>
  <id_info>
    <org_study_id>2017003001</org_study_id>
    <secondary_id>2017-001090-16</secondary_id>
    <nct_id>NCT03190694</nct_id>
  </id_info>
  <brief_title>Effects of Dapagliflozin in Non-diabetic Patients With Proteinuria</brief_title>
  <acronym>DIAMOND</acronym>
  <official_title>A Study to Assess the Renoprotective Effects of the SGLT2 Inhibitor Dapagliflozin in Non-Diabetic Patients With Proteinuria: a Randomized Double Blind 6-Weeks Cross-Over Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hiddo Lambers Heerspink</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Medical Center Groningen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study tests the hypothesis that dapagliflozin lowers proteinuria in patients with&#xD;
      non-diabetic chronic kidney disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Despite optimal treatment with renin-angiotensin-aldosterone-system (RAAS) inhibitors, many&#xD;
      patients with non-diabetic kidney disease show progressive kidney function loss, which is&#xD;
      associated with high residual proteinuria. Novel treatment strategies are therefore required&#xD;
      to further decrease proteinuria and to slow kidney function decline.&#xD;
&#xD;
      Dapagliflozin is a sodium-glucose transport (SGLT2) inhibitor and inhibits the reabsorption&#xD;
      of glucose and sodium in the proximal tubule. The increased natriuresis following&#xD;
      dapagliflozin administration normalizes tubuloglomerular feedback resulting in a reduction in&#xD;
      intra-glomerular hypertension, which is in turn manifested by acute reversible reductions in&#xD;
      glomerular filtration rate and albuminuria. Since many etiologies of non-diabetic nephropathy&#xD;
      are characterized by intraglomerular hypertension, we hypothesize that dapagliflozin acutely&#xD;
      decreases GFR and proteinuria in patients without diabetes at risk of progressive kidney&#xD;
      function loss via a glucose independent hemodynamic mechanism.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date type="Actual">November 12, 2017</start_date>
  <completion_date type="Anticipated">December 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>A Randomized Double Blind 6-Weeks Cross-over</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in 24-hr proteinuria with dapagliflozin for six weeks relative to placebo in patients with non-diabetic kidney disease and proteinuria 500 mg/day on stable angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker treatment.</measure>
    <time_frame>6 weeks</time_frame>
    <description>bioequivalence</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of dapagliflozin 10 mg/d compared to placebo on Glomerular Filtration Rate (GFR) using iohexol clearance</measure>
    <time_frame>6 weeks</time_frame>
    <description>bioequivalence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of dapagliflozin 10 mg/d compared to placebo on systolic/diastolic blood pressure</measure>
    <time_frame>week 0, 2, 4, 5, 6, 12, 15, 18, 24</time_frame>
    <description>bioequivalence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of dapagliflozin 10 mg/d compared to placebo on body weight</measure>
    <time_frame>week 0, 2, 4, 5, 6, 12, 15, 18, 24</time_frame>
    <description>bioequivalence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of dapagliflozin 10 mg/d compared to placebo on selected neurohormones/ biomarkers</measure>
    <time_frame>week 0, 3, 6, 12, 15, 18, 24</time_frame>
    <description>bioequivalence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of dapagliflozin vs. placebo - the number of hypoglycemia episodes between groups and serious adverse events</measure>
    <time_frame>week 0-26</time_frame>
    <description>safety</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Chronic Kidney Diseases</condition>
  <condition>Proteinuria</condition>
  <arm_group>
    <arm_group_label>Dapagliflozin 10mg Tablet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 mg Green, plain, diamond shaped, film coated tablet (orally)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Matching Dapagliflozin Tablet</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Green, plain, diamond shaped, film coated tablet. Does not contain active ingredient</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapagliflozin 10mg</intervention_name>
    <description>Tablet</description>
    <arm_group_label>Dapagliflozin 10mg Tablet</arm_group_label>
    <arm_group_label>Placebo Matching Dapagliflozin Tablet</arm_group_label>
    <other_name>Placebo Matching Dapagliflozin 10mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥18 and ≤75 years&#xD;
&#xD;
          -  Urinary protein excretion &gt; 500 mg/g and ≤ 3500 mg/g in a 24-hr urine collection eGFR&#xD;
             ≥ 25 mL/min/1.73m2&#xD;
&#xD;
          -  On a stable dose of an ACEi or ARB for at least 4 weeks prior to randomization&#xD;
&#xD;
          -  Willing to sign informed consent&#xD;
&#xD;
          -  Women of Child-Bearing Potential (WOCBP):&#xD;
&#xD;
          -  WOCBP must be using an acceptable method of contraception to avoid pregnancy&#xD;
             throughout the study and for up to 4 weeks after the last dose of study drug in such a&#xD;
             manner that the risk of pregnancy is minimized.&#xD;
&#xD;
          -  WOCBP must have a negative serum or urine pregnancy test result (minimum sensitivity&#xD;
             25 IU/L or equivalent units of HCG) within 0 to 72 hours before the first dose of&#xD;
             study drug.&#xD;
&#xD;
          -  Women must not be breast-feeding.&#xD;
&#xD;
        WOCBP comprises women who have experienced menarche and who have not undergone successful&#xD;
        surgical sterilization (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy)&#xD;
        or who are not post-menopausal.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of type 1 or type 2 diabetes mellitus&#xD;
&#xD;
          -  Urinary protein excretion &gt; 3500 mg/day&#xD;
&#xD;
          -  Autosomal dominant polycystic kidney disease or autosomal recessive polycystic kidney&#xD;
             disease, lupus nephritis, or ANCA-associated vasculitis&#xD;
&#xD;
          -  Indication for immunosuppressants as per the treating physician's judgment.&#xD;
&#xD;
          -  Receiving cytotoxic therapy, immunosuppressive therapy, or other immunotherapy for&#xD;
             primary or secondary renal disease within 6 months prior to enrolment.&#xD;
&#xD;
          -  Active malignancy aside from treated squamous cell or basal cell carcinoma of the&#xD;
             skin.&#xD;
&#xD;
          -  Any medication, surgical or medical condition which might significantly alter the&#xD;
             absorption, distribution, metabolism, or excretion of medications including, but not&#xD;
             limited to any of the following:&#xD;
&#xD;
               -  History of active inflammatory bowel disease within the last six months;&#xD;
&#xD;
               -  Major gastrointestinal tract surgery such as gastrectomy, gastroenterostomy, or&#xD;
                  bowel resection;&#xD;
&#xD;
               -  Gastro-intestinal ulcers and/or gastrointestinal or rectal bleeding within last&#xD;
                  six months;&#xD;
&#xD;
               -  Pancreatic injury or pancreatitis within the last six months;&#xD;
&#xD;
               -  Evidence of hepatic disease as determined by any one of the following: ALT or AST&#xD;
                  values exceeding 3x ULN at the screening visit, a history of hepatic&#xD;
                  encephalopathy, a history of esophageal varices, or a history of portocaval&#xD;
                  shunt;&#xD;
&#xD;
               -  Evidence of urinary obstruction of difficulty in voiding at screening&#xD;
&#xD;
          -  History of severe hypersensitivity or contraindications to dapagliflozin&#xD;
&#xD;
          -  Subject who, in the assessment of the investigator, may be at risk for dehydration or&#xD;
             volume depletion that may affect the interpretation of efficacy or safety data&#xD;
&#xD;
          -  Participation in any clinical investigation within 3 months prior to initial dosing.&#xD;
&#xD;
          -  Donation or loss of 400 ml or more of blood within 8 weeks prior to initial dosing.&#xD;
&#xD;
          -  History of drug or alcohol abuse within the 12 months prior to dosing, or evidence of&#xD;
             such abuse as indicated by the laboratory assays conducted during the screening.&#xD;
&#xD;
          -  History of noncompliance to medical regimens or unwillingness to comply with the study&#xD;
             protocol.&#xD;
&#xD;
          -  Any surgical or medical condition, which in the opinion of the investigator, may place&#xD;
             the patient at higher risk from his/her participation in the study, or is likely to&#xD;
             prevent the patient from complying with the requirements of the study or completing&#xD;
             the study.&#xD;
&#xD;
          -  Pregnancy or breastfeeding&#xD;
&#xD;
          -  WOCBP who are unwilling or unable to use an acceptable method to avoid pregnancy for&#xD;
             the entire study period and up to 4 weeks after the last dose of study drug.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Nephrology Dept., Vancouver Coastal Health Research Institute</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Division of Nephrology University Health Network, University of Toronto</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nephrology Unit, University Kebangsaan Malaysia</name>
      <address>
        <city>Kuala Lumpur</city>
        <zip>5600</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Malaya Medical Centre, Ward 8TE</name>
      <address>
        <city>Kuala Lumpur</city>
        <zip>59100</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept Internal Medicine, division of Nephrology Hospital Group Twente</name>
      <address>
        <city>Almelo</city>
        <zip>7609 PP</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept.of Nephrology, VU University Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <zip>1081 HV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. Nephrology, University Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9713 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Malaysia</country>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>June 15, 2017</study_first_submitted>
  <study_first_submitted_qc>June 16, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 19, 2017</study_first_posted>
  <last_update_submitted>September 25, 2019</last_update_submitted>
  <last_update_submitted_qc>September 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 27, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University Medical Center Groningen</investigator_affiliation>
    <investigator_full_name>Hiddo Lambers Heerspink</investigator_full_name>
    <investigator_title>Clinical Pharmacologist</investigator_title>
  </responsible_party>
  <keyword>chronic kidney disease</keyword>
  <keyword>non diabetic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Proteinuria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dapagliflozin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

